Jubilant co to sell stake in US firm for $139 million
11 months ago
16
NEW DELHI:
Jubilant Pharmova's subsidiary
Jubilant Pharma will sell its entire 25.8% stake in US-based Sofie Biosciences for $139.4 million. Singapore-based Jubilant Pharma invested $25 million in Sofie in November 2020, says a company statement. Sofie is engaged in developing and delivering molecular diagnostics and therapeutics (theranostics). It has radiopharmaceutical production and distribution network, mature contract manufacturing services and high value theranostic intellectual property.
It has now entered into a definitive merger agreement with certain private equity funds.
We invite you to explore our website, engage with our content, and become part of our community. Thank you for trusting us as your go-to destination for news that matters.
Certain articles, images, or other media on this website may be sourced from external contributors, agencies, or organizations. In such cases, we make every effort to provide proper attribution, acknowledging the original source of the content.
If you believe that your copyrighted work has been used on our site in a way that constitutes copyright infringement, please contact us promptly. We are committed to addressing and rectifying any such instances
English (US) ·